Nasdaq

QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing

QuidelOrtho Corporation QDEL recently announced the FDA 510(k) clearance for its QuickVue COVID-19 test.With CLIA certificates of waiver, this approval permits the test to be used accurately and ...
AOL

The best FDA-approved at-home COVID tests

At present, the FDA lists over forty emergency-use approved at-home COVID tests on its website from over thirty different brands. Some tests are rapid at-home antigen tests that give results in as ...
Nasdaq

QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test

Designed for symptomatic individuals within six days of symptom onset, the QuickVue COVID-19 test is cleared for use in individuals aged 14 or older when self-testing, and in those aged two and older ...

At-home lab tests promise answers—but do they deliver?

This article was reviewed by Darragh O’Carroll, MD. Pros, Cons & Benefits of At-Home Lab Testing You probably don’t have time ...
Hosted on MSN

QuidelOrtho announces availability of QUICKVUE Influenza + SARS Test

QuidelOrtho (QDEL) is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)-cleared rapid, easy-to-use immunoassay designed for professional use in physician ...
Business Wire

QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 ...